{"url_path":"/sec/evmn/8-k/2026-06-29/item-9-01","section_key":"item-9-01","section_title":"Item 9.01 Financial Statements and Exhibits.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-29","source_url":"https://www.sec.gov/Archives/edgar/data/2044725/0001193125-26-286918-index.html","accession_number":"0001193125-26-286918","cik":"0002044725","ticker":"EVMN","issuer_name":"Evommune, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/2044725/0001193125-26-286918-index.html","primary_entity_key":"0002044725","primary_entity_name":"Evommune, Inc."},"word_count":95,"has_tables":true,"body_markdown":"Item 9.01 Financial Statements and Exhibits.\n\n(d) Exhibits.\n\n \n\nExhibit\n\nNumber\n\nDescription\n\n99.1\n\n \n\n[Press Release, dated June 29, 2026, titled \"Evommune Announces Top-line Results from EVO756 Phase 2b Trial in Moderate-to-Severe Chronic Spontaneous Urticaria\"](evmn-ex99_1.htm)\n\n104\n\nCover Page Interactive Data File (embedded within the Inline XBRL document)\n\n \n\n1\n\n \n\nSIGNATURES\n\nPursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.\n\n \n\nEvommune, Inc.\n\nDate: June 29, 2026\n\nBy:\n\n/s/ Luis Peña\n\nLuis Peña\n\nPresident and Chief Executive Officer\n\n \n\n2"}